In partnership with Observia, the Giropharm group of community pharmacists wants to strengthen its role as a public health player and demonstrate its added value in patient compliance.
Announced at the end of 2013, the Giroprevent project is now taking shape. This "investigation group for recommendations on adherence and prevention" in pharmacies was launched by the Giropharm pharmacy group in partnership with Observia, a company specializing in e-health. The progress report was presented to the press on June 24. The objective: to demonstrate, through real-life studies, the relevance of pharmacist intervention in improving patient adherence and preventing potential complications and recurrences.
In a context of evolving pharmaceutical business models, Jean-Christophe Lauzeral, Operational Director of Giropharm, points to a "convergence of interests" between pharmacies and ethical laboratories. The latter's portfolio is transforming, with high-value products aimed at limited populations, at high prices, and whose reimbursement is subject to "good management."
"These laboratories like AbbVie, MSD, and Roche are new partners for us," he says happily. While pharmaceutical companies must now prove the value of their products in real-life situations, pharmacists, for their part, hope to strengthen their mission as healthcare providers "outside the conventional sphere."
“Because of their proximity to the patient, the pharmacist has a key role to play in support and compliance, and would be legitimate to be involved in the conduct of these real-life studies,” believes Stéphanie Corre Le Bail, director of the health, quality and training division newly set up by Giropharm.”
Source: http://www.pharmaceutiques.com
To find out more: http://www.commerce-associe.fr/actualites-des-enseignes